Diabetic Nephropathy and Gaseous Modulators.
Subir Kumar JuinRosemary OusephDibson Dibe GondimVenkatakrishna Rao JalaUtpal SenPublished in: Antioxidants (Basel, Switzerland) (2023)
Diabetic nephropathy (DN) remains the leading cause of vascular morbidity and mortality in diabetes patients. Despite the progress in understanding the diabetic disease process and advanced management of nephropathy, a number of patients still progress to end-stage renal disease (ESRD). The underlying mechanism still needs to be clarified. Gaseous signaling molecules, so-called gasotransmitters, such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H 2 S), have been shown to play an essential role in the development, progression, and ramification of DN depending on their availability and physiological actions. Although the studies on gasotransmitter regulations of DN are still emerging, the evidence revealed an aberrant level of gasotransmitters in patients with diabetes. In studies, different gasotransmitter donors have been implicated in ameliorating diabetic renal dysfunction. In this perspective, we summarized an overview of the recent advances in the physiological relevance of the gaseous molecules and their multifaceted interaction with other potential factors, such as extracellular matrix (ECM), in the severity modulation of DN. Moreover, the perspective of the present review highlights the possible therapeutic interventions of gasotransmitters in ameliorating this dreaded disease.
Keyphrases
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- diabetic nephropathy
- extracellular matrix
- type diabetes
- nitric oxide
- ejection fraction
- prognostic factors
- newly diagnosed
- cardiovascular disease
- small molecule
- adipose tissue
- single cell
- insulin resistance
- glycemic control
- skeletal muscle
- case control
- climate change
- nitric oxide synthase
- kidney transplantation